Luminal tumours have been associated with favourable prognosis with 80–85% survival at 5 years; while the triple negative and HER2 positive are associated with poor prognoses, with a high risk of recurrence in a period of 3 years and a high mortality rate in 5 years, with survival rate decreases to 50–60% [6, 8]. Here, ERBB2 is linked to neoplasm.